<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34828382</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4425</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>11</Issue><PubDate><Year>2021</Year><Month>Nov</Month><Day>09</Day></PubDate></JournalIssue><Title>Genes</Title><ISOAbbreviation>Genes (Basel)</ISOAbbreviation></Journal><ArticleTitle>NAD<sup>+</sup> Metabolism and Diseases with Motor Dysfunction.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1776</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/genes12111776</ELocationID><Abstract><AbstractText>Neurodegenerative diseases result in the progressive deterioration of the nervous system, with motor and cognitive impairments being the two most observable problems. Motor dysfunction could be caused by motor neuron diseases (MNDs) characterized by the loss of motor neurons, such as amyotrophic lateral sclerosis and Charcot-Marie-Tooth disease, or other neurodegenerative diseases with the destruction of brain areas that affect movement, such as Parkinson's disease and Huntington's disease. Nicotinamide adenine dinucleotide (NAD<sup>+</sup>) is one of the most abundant metabolites in the human body and is involved with numerous cellular processes, including energy metabolism, circadian clock, and DNA repair. NAD<sup>+</sup> can be reversibly oxidized-reduced or directly consumed by NAD<sup>+</sup>-dependent proteins. NAD<sup>+</sup> is synthesized in cells via three different paths: the de novo, Preiss-Handler, or NAD<sup>+</sup> salvage pathways, with the salvage pathway being the primary producer of NAD<sup>+</sup> in mammalian cells. NAD<sup>+</sup> metabolism is being investigated for a role in the development of neurodegenerative diseases. In this review, we discuss cellular NAD<sup>+</sup> homeostasis, looking at NAD<sup>+</sup> biosynthesis and consumption, with a focus on the NAD<sup>+</sup> salvage pathway. Then, we examine the research, including human clinical trials, focused on the involvement of NAD<sup>+</sup> in MNDs and other neurodegenerative diseases with motor dysfunction.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lundt</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Dalton Cardiovascular Research Center, University of Missouri-Columbia, Columbia, MO 65211, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Interdisciplinary Neuroscience Program, University of Missouri-Columbia, Columbia, MO 65211, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Shinghua</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Dalton Cardiovascular Research Center, University of Missouri-Columbia, Columbia, MO 65211, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical, Biological and Chemical Engineering, University of Missouri-Columbia, Columbia, MO 65211, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS094539</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS069726</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Genes (Basel)</MedlineTA><NlmUniqueID>101551097</NlmUniqueID><ISSNLinking>2073-4425</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0U46U6E8UK</RegistryNumber><NameOfSubstance UI="D009243">NAD</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002607" MajorTopicYN="N">Charcot-Marie-Tooth Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057906" MajorTopicYN="N">Circadian Clocks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004260" MajorTopicYN="N">DNA Repair</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004734" MajorTopicYN="N">Energy Metabolism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009243" MajorTopicYN="N">NAD</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">NAD+</Keyword><Keyword MajorTopicYN="N">Nampt</Keyword><Keyword MajorTopicYN="N">energy metabolism</Keyword><Keyword MajorTopicYN="N">motor dysfunction</Keyword><Keyword MajorTopicYN="N">motor neuron diseases</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>27</Day><Hour>1</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34828382</ArticleId><ArticleId IdType="pmc">PMC8625820</ArticleId><ArticleId IdType="doi">10.3390/genes12111776</ArticleId><ArticleId IdType="pii">genes12111776</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dugger B.N., Dickson D.W. Pathology of Neurodegenerative Diseases. Cold Spring Harb. Perspect. Biol. 2017;9:a028035. doi: 10.1101/cshperspect.a028035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a028035</ArticleId><ArticleId IdType="pmc">PMC5495060</ArticleId><ArticleId IdType="pubmed">28062563</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaszczyk J.W. Energy Metabolism Decline in the Aging Brain-Pathogenesis of Neurodegenerative Disorders. Metabolites. 2020;10:450. doi: 10.3390/metabo10110450.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/metabo10110450</ArticleId><ArticleId IdType="pmc">PMC7695180</ArticleId><ArticleId IdType="pubmed">33171879</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman S.A. Diagnosis and Clinical Management of Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders. Continuum. 2017;23:1332&#x2013;1359. doi: 10.1212/CON.0000000000000535.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/CON.0000000000000535</ArticleId><ArticleId IdType="pubmed">28968365</ArticleId></ArticleIdList></Reference><Reference><Citation>Ragagnin A.M.G., Shadfar S., Vidal M., Jamali M.S., Atkin J.D. Motor Neuron Susceptibility in ALS/FTD. Front. Neurosci. 2019;13:532. doi: 10.3389/fnins.2019.00532.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00532</ArticleId><ArticleId IdType="pmc">PMC6610326</ArticleId><ArticleId IdType="pubmed">31316328</ArticleId></ArticleIdList></Reference><Reference><Citation>Murthy M., Cheng Y.Y., Holton J.L., Bettencourt C. Neurodegenerative movement disorders: An epigenetics perspective and promise for the future. Neuropathol. Appl. Neurobiol. 2021:1&#x2013;13. doi: 10.1111/nan.12757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12757</ArticleId><ArticleId IdType="pubmed">34318515</ArticleId></ArticleIdList></Reference><Reference><Citation>Lautrup S., Sinclair D.A., Mattson M.P., Fang E.F. NAD+ in Brain Aging and Neurodegenerative Disorders. Cell Metab. 2019;30:630&#x2013;655. doi: 10.1016/j.cmet.2019.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2019.09.001</ArticleId><ArticleId IdType="pmc">PMC6787556</ArticleId><ArticleId IdType="pubmed">31577933</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdin E. NAD+ in aging, metabolism, and neurodegeneration. Science. 2015;350:1208&#x2013;1213. doi: 10.1126/science.aac4854.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aac4854</ArticleId><ArticleId IdType="pubmed">26785480</ArticleId></ArticleIdList></Reference><Reference><Citation>Pieper A.A., McKnight S.L. Benefits of Enhancing Nicotinamide Adenine Dinucleotide Levels in Damaged or Diseased Nerve Cells. Cold Spring Harb. Symp. Quant. Biol. 2018;83:207&#x2013;217. doi: 10.1101/sqb.2018.83.037622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/sqb.2018.83.037622</ArticleId><ArticleId IdType="pubmed">30787047</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajman L., Chwalek K., Sinclair D.A. Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. Cell Metab. 2018;27:529&#x2013;547. doi: 10.1016/j.cmet.2018.02.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2018.02.011</ArticleId><ArticleId IdType="pmc">PMC6342515</ArticleId><ArticleId IdType="pubmed">29514064</ArticleId></ArticleIdList></Reference><Reference><Citation>Canto C., Menzies K.J., Auwerx J. NAD+ Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the Nucleus. Cell Metab. 2015;22:31&#x2013;53. doi: 10.1016/j.cmet.2015.05.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2015.05.023</ArticleId><ArticleId IdType="pmc">PMC4487780</ArticleId><ArticleId IdType="pubmed">26118927</ArticleId></ArticleIdList></Reference><Reference><Citation>Covarrubias A.J., Perrone R., Grozio A., Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nat. Rev. Mol. Cell Biol. 2021;22:119&#x2013;141. doi: 10.1038/s41580-020-00313-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-020-00313-x</ArticleId><ArticleId IdType="pmc">PMC7963035</ArticleId><ArticleId IdType="pubmed">33353981</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasperi V., Sibilano M., Savini I., Catani M.V. Niacin in the Central Nervous System: An Update of Biological Aspects and Clinical Applications. Int. J. Mol. Sci. 2019;20:974. doi: 10.3390/ijms20040974.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20040974</ArticleId><ArticleId IdType="pmc">PMC6412771</ArticleId><ArticleId IdType="pubmed">30813414</ArticleId></ArticleIdList></Reference><Reference><Citation>Rongvaux A., Andris F., Van Gool F., Leo O. Reconstructing eukaryotic NAD metabolism. Bioessays. 2003;25:683&#x2013;690. doi: 10.1002/bies.10297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bies.10297</ArticleId><ArticleId IdType="pubmed">12815723</ArticleId></ArticleIdList></Reference><Reference><Citation>Revollo J.R., Grimm A.A., Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J. Biol. Chem. 2004;279:50754&#x2013;50763. doi: 10.1074/jbc.M408388200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M408388200</ArticleId><ArticleId IdType="pubmed">15381699</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W., Xie Y., Wang T., Bi J., Li H., Zhang L.Q., Ye S.Q., Ding S. Neuronal protective role of PBEF in a mouse model of cerebral ischemia. J. Cereb. Blood Flow Metab. 2010;30:1962&#x2013;1971. doi: 10.1038/jcbfm.2010.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jcbfm.2010.71</ArticleId><ArticleId IdType="pmc">PMC3002881</ArticleId><ArticleId IdType="pubmed">20485294</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsyuba E., Auwerx J. Modulating NAD+ metabolism, from bench to bedside. EMBO J. 2017;36:2670&#x2013;2683. doi: 10.15252/embj.201797135.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201797135</ArticleId><ArticleId IdType="pmc">PMC5599801</ArticleId><ArticleId IdType="pubmed">28784597</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger F., Lau C., Dahlmann M., Ziegler M. Subcellular compartmentation and differential catalytic properties of the three human nicotinamide mononucleotide adenylyltransferase isoforms. J. Biol. Chem. 2005;280:36334&#x2013;36341. doi: 10.1074/jbc.M508660200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M508660200</ArticleId><ArticleId IdType="pubmed">16118205</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilley J., Adalbert R., Yu G., Coleman M.P. Rescue of peripheral and CNS axon defects in mice lacking NMNAT2. J. Neurosci. 2013;33:13410&#x2013;13424. doi: 10.1523/JNEUROSCI.1534-13.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1534-13.2013</ArticleId><ArticleId IdType="pmc">PMC6705152</ArticleId><ArticleId IdType="pubmed">23946398</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilley J., Mayer P.R., Yu G., Coleman M.P. Low levels of NMNAT2 compromise axon development and survival. Hum. Mol. Genet. 2019;28:448&#x2013;458. doi: 10.1093/hmg/ddy356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddy356</ArticleId><ArticleId IdType="pubmed">30304512</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo A., Goel P., Brace E.J., Buser C., Dickman D., DiAntonio A. The E3 ligase Highwire promotes synaptic transmission by targeting the NAD-synthesizing enzyme dNmnat. EMBO Rep. 2019;20:e46975. doi: 10.15252/embr.201846975.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embr.201846975</ArticleId><ArticleId IdType="pmc">PMC6399608</ArticleId><ArticleId IdType="pubmed">30692130</ArticleId></ArticleIdList></Reference><Reference><Citation>Bieganowski P., Brenner C. Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans. Cell. 2004;117:495&#x2013;502. doi: 10.1016/S0092-8674(04)00416-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(04)00416-7</ArticleId><ArticleId IdType="pubmed">15137942</ArticleId></ArticleIdList></Reference><Reference><Citation>Fletcher R.S., Ratajczak J., Doig C.L., Oakey L.A., Callingham R., Da Silva Xavier G., Garten A., Elhassan Y.S., Redpath P., Migaud M.E., et al. Nicotinamide riboside kinases display redundancy in mediating nicotinamide mononucleotide and nicotinamide riboside metabolism in skeletal muscle cells. Mol. Metab. 2017;6:819&#x2013;832. doi: 10.1016/j.molmet.2017.05.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmet.2017.05.011</ArticleId><ArticleId IdType="pmc">PMC5518663</ArticleId><ArticleId IdType="pubmed">28752046</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang E.F., Lautrup S., Hou Y., Demarest T.G., Croteau D.L., Mattson M.P., Bohr V.A. NAD+ in Aging: Molecular Mechanisms and Translational Implications. Trends Mol. Med. 2017;23:899&#x2013;916. doi: 10.1016/j.molmed.2017.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2017.08.001</ArticleId><ArticleId IdType="pmc">PMC7494058</ArticleId><ArticleId IdType="pubmed">28899755</ArticleId></ArticleIdList></Reference><Reference><Citation>Cambronne X.A., Stewart M.L., Kim D., Jones-Brunette A.M., Morgan R.K., Farrens D.L., Cohen M.S., Goodman R.H. Biosensor reveals multiple sources for mitochondrial NAD+ Science. 2016;352:1474&#x2013;1477. doi: 10.1126/science.aad5168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aad5168</ArticleId><ArticleId IdType="pmc">PMC6530784</ArticleId><ArticleId IdType="pubmed">27313049</ArticleId></ArticleIdList></Reference><Reference><Citation>Garten A., Schuster S., Penke M., Gorski T., de Giorgis T., Kiess W. Physiological and pathophysiological roles of NAMPT and NAD metabolism. Nat. Rev. Endocrinol. 2015;11:535&#x2013;546. doi: 10.1038/nrendo.2015.117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrendo.2015.117</ArticleId><ArticleId IdType="pubmed">26215259</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshino J., Baur J.A., Imai S.I. NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR. Cell Metab. 2018;27:513&#x2013;528. doi: 10.1016/j.cmet.2017.11.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2017.11.002</ArticleId><ArticleId IdType="pmc">PMC5842119</ArticleId><ArticleId IdType="pubmed">29249689</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitani T., Okuno S., Fujisawa H. Growth phase-dependent changes in the subcellular localization of pre-B-cell colony-enhancing factor. FEBS Lett. 2003;544:74&#x2013;78. doi: 10.1016/S0014-5793(03)00476-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-5793(03)00476-9</ArticleId><ArticleId IdType="pubmed">12782293</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H., Yang T., Baur J.A., Perez E., Matsui T., Carmona J.J., Lamming D.W., Souza-Pinto N.C., Bohr V.A., Rosenzweig A., et al. Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell. 2007;130:1095&#x2013;1107. doi: 10.1016/j.cell.2007.07.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2007.07.035</ArticleId><ArticleId IdType="pmc">PMC3366687</ArticleId><ArticleId IdType="pubmed">17889652</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittelli M., Formentini L., Faraco G., Lapucci A., Rapizzi E., Cialdai F., Romano G., Moneti G., Moroni F., Chiarugi A. Inhibition of nicotinamide phosphoribosyltransferase: Cellular bioenergetics reveals a mitochondrial insensitive NAD pool. J. Biol. Chem. 2010;285:34106&#x2013;34114. doi: 10.1074/jbc.M110.136739.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.136739</ArticleId><ArticleId IdType="pmc">PMC2962509</ArticleId><ArticleId IdType="pubmed">20724478</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris-Blanco K.C., Cohan C.H., Neumann J.T., Sick T.J., Perez-Pinzon M.A. Protein kinase C epsilon regulates mitochondrial pools of Nampt and NAD following resveratrol and ischemic preconditioning in the rat cortex. J. Cereb. Blood Flow Metab. 2014;34:1024&#x2013;1032. doi: 10.1038/jcbfm.2014.51.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jcbfm.2014.51</ArticleId><ArticleId IdType="pmc">PMC4050248</ArticleId><ArticleId IdType="pubmed">24667915</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Zhang Z., Zhang N., Li H., Zhang L., Baines C.P., Ding S. Subcellular NAMPT-mediated NAD+ salvage pathways and their roles in bioenergetics and neuronal protection after ischemic injury. J. Neurochem. 2019;151:732&#x2013;748. doi: 10.1111/jnc.14878.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.14878</ArticleId><ArticleId IdType="pmc">PMC6917901</ArticleId><ArticleId IdType="pubmed">31553812</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogan K.L., Brenner C. Nicotinic acid, nicotinamide, and nicotinamide riboside: A molecular evaluation of NAD+ precursor vitamins in human nutrition. Annu. Rev. Nutr. 2008;28:115&#x2013;130. doi: 10.1146/annurev.nutr.28.061807.155443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.nutr.28.061807.155443</ArticleId><ArticleId IdType="pubmed">18429699</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori V., Amici A., Mazzola F., Di Stefano M., Conforti L., Magni G., Ruggieri S., Raffaelli N., Orsomando G. Metabolic profiling of alternative NAD biosynthetic routes in mouse tissues. PLoS ONE. 2014;9:e113939. doi: 10.1371/journal.pone.0113939.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0113939</ArticleId><ArticleId IdType="pmc">PMC4244216</ArticleId><ArticleId IdType="pubmed">25423279</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujigaki H., Yamamoto Y., Saito K. L-Tryptophan-kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: Focus on cell type differences. Neuropharmacology. 2017;112:264&#x2013;274. doi: 10.1016/j.neuropharm.2016.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2016.01.011</ArticleId><ArticleId IdType="pubmed">26767951</ArticleId></ArticleIdList></Reference><Reference><Citation>Revollo J.R., Korner A., Mills K.F., Satoh A., Wang T., Garten A., Dasgupta B., Sasaki Y., Wolberger C., Townsend R.R., et al. Nampt/PBEF/Visfatin regulates insulin secretion in &#x3b2; cells as a systemic NAD biosynthetic enzyme. Cell Metab. 2007;6:363&#x2013;375. doi: 10.1016/j.cmet.2007.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2007.09.003</ArticleId><ArticleId IdType="pmc">PMC2098698</ArticleId><ArticleId IdType="pubmed">17983582</ArticleId></ArticleIdList></Reference><Reference><Citation>Jing Z., Xing J., Chen X., Stetler R.A., Weng Z., Gan Y., Zhang F., Gao Y., Chen J., Leak R.K., et al. Neuronal NAMPT is released after cerebral ischemia and protects against white matter injury. J. Cereb. Blood Flow Metab. 2014;34:1613&#x2013;1621. doi: 10.1038/jcbfm.2014.119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jcbfm.2014.119</ArticleId><ArticleId IdType="pmc">PMC4269719</ArticleId><ArticleId IdType="pubmed">25005877</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P., Xu T.Y., Guan Y.F., Tian W.W., Viollet B., Rui Y.C., Zhai Q.W., Su D.F., Miao C.Y. Nicotinamide phosphoribosyltransferase protects against ischemic stroke through SIRT1-dependent adenosine monophosphate-activated kinase pathway. Ann. Neurol. 2011;69:360&#x2013;374. doi: 10.1002/ana.22236.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22236</ArticleId><ArticleId IdType="pubmed">21246601</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein L.R., Imai S. Specific ablation of Nampt in adult neural stem cells recapitulates their functional defects during aging. EMBO J. 2014;33:1321&#x2013;1340. doi: 10.1002/embj.201386917.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/embj.201386917</ArticleId><ArticleId IdType="pmc">PMC4194122</ArticleId><ArticleId IdType="pubmed">24811750</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L.Y., Wang F., Zhang X.Y., Huang P., Lu Y.B., Wei E.Q., Zhang W.P. Nicotinamide phosphoribosyltransferase may be involved in age-related brain diseases. PLoS ONE. 2012;7:e44933. doi: 10.1371/journal.pone.0044933.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0044933</ArticleId><ArticleId IdType="pmc">PMC3469563</ArticleId><ArticleId IdType="pubmed">23071504</ArticleId></ArticleIdList></Reference><Reference><Citation>Caton P.W., Kieswich J., Yaqoob M.M., Holness M.J., Sugden M.C. Nicotinamide mononucleotide protects against pro-inflammatory cytokine-mediated impairment of mouse islet function. Diabetologia. 2011;54:3083&#x2013;3092. doi: 10.1007/s00125-011-2288-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-011-2288-0</ArticleId><ArticleId IdType="pubmed">21901281</ArticleId></ArticleIdList></Reference><Reference><Citation>Garten A., Petzold S., Barnikol-Oettler A., Korner A., Thasler W.E., Kratzsch J., Kiess W., Gebhardt R. Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes. Biochem. Biophys. Res. Commun. 2010;391:376&#x2013;381. doi: 10.1016/j.bbrc.2009.11.066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2009.11.066</ArticleId><ArticleId IdType="pubmed">19912992</ArticleId></ArticleIdList></Reference><Reference><Citation>Friebe D., Neef M., Kratzsch J., Erbs S., Dittrich K., Garten A., Petzold-Quinque S., Bluher S., Reinehr T., Stumvoll M., et al. Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase (NAMPT)/pre-B cell colony (PBEF)/visfatin linking obesity and inflammation in humans. Diabetologia. 2011;54:1200&#x2013;1211. doi: 10.1007/s00125-010-2042-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-010-2042-z</ArticleId><ArticleId IdType="pmc">PMC3071946</ArticleId><ArticleId IdType="pubmed">21298414</ArticleId></ArticleIdList></Reference><Reference><Citation>Curat C.A., Wegner V., Sengenes C., Miranville A., Tonus C., Busse R., Bouloumie A. Macrophages in human visceral adipose tissue: Increased accumulation in obesity and a source of resistin and visfatin. Diabetologia. 2006;49:744&#x2013;747. doi: 10.1007/s00125-006-0173-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-006-0173-z</ArticleId><ArticleId IdType="pubmed">16496121</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida M., Satoh A., Lin J.B., Mills K.F., Sasaki Y., Rensing N., Wong M., Apte R.S., Imai S.I. Extracellular Vesicle-Contained eNAMPT Delays Aging and Extends Lifespan in Mice. Cell Metab. 2019;30:329&#x2013;342. doi: 10.1016/j.cmet.2019.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2019.05.015</ArticleId><ArticleId IdType="pmc">PMC6687560</ArticleId><ArticleId IdType="pubmed">31204283</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Zhang Q., Bao R., Zhang N., Wang Y., Polo-Parada L., Tarim A., Alemifar A., Han X., Wilkins H.M., et al. Deletion of Nampt in Projection Neurons of Adult Mice Leads to Motor Dysfunction, Neurodegeneration, and Death. Cell Rep. 2017;20:2184&#x2013;2200. doi: 10.1016/j.celrep.2017.08.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.08.022</ArticleId><ArticleId IdType="pmc">PMC6021762</ArticleId><ArticleId IdType="pubmed">28854367</ArticleId></ArticleIdList></Reference><Reference><Citation>Imai S., Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 2014;24:464&#x2013;471. doi: 10.1016/j.tcb.2014.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcb.2014.04.002</ArticleId><ArticleId IdType="pmc">PMC4112140</ArticleId><ArticleId IdType="pubmed">24786309</ArticleId></ArticleIdList></Reference><Reference><Citation>Agerholm M., Dall M., Jensen B.A.H., Prats C., Madsen S., Basse A.L., Graae A.S., Risis S., Goldenbaum J., Quistorff B., et al. Perturbations of NAD+ salvage systems impact mitochondrial function and energy homeostasis in mouse myoblasts and intact skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 2018;314:E377&#x2013;E395. doi: 10.1152/ajpendo.00213.2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpendo.00213.2017</ArticleId><ArticleId IdType="pubmed">29208611</ArticleId></ArticleIdList></Reference><Reference><Citation>Costford S.R., Brouwers B., Hopf M.E., Sparks L.M., Dispagna M., Gomes A.P., Cornnell H.H., Petucci C., Phelan P., Xie H., et al. Skeletal muscle overexpression of nicotinamide phosphoribosyl transferase in mice coupled with voluntary exercise augments exercise endurance. Mol. Metab. 2018;7:1&#x2013;11. doi: 10.1016/j.molmet.2017.10.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmet.2017.10.012</ArticleId><ArticleId IdType="pmc">PMC5784330</ArticleId><ArticleId IdType="pubmed">29146412</ArticleId></ArticleIdList></Reference><Reference><Citation>Frederick D.W., Davis J.G., Davila A., Jr., Agarwal B., Michan S., Puchowicz M.A., Nakamaru-Ogiso E., Baur J.A. Increasing NAD synthesis in muscle via nicotinamide phosphoribosyltransferase is not sufficient to promote oxidative metabolism. J. Biol. Chem. 2015;290:1546&#x2013;1558. doi: 10.1074/jbc.M114.579565.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.579565</ArticleId><ArticleId IdType="pmc">PMC4340401</ArticleId><ArticleId IdType="pubmed">25411251</ArticleId></ArticleIdList></Reference><Reference><Citation>Frederick D.W., Loro E., Liu L., Davila A., Jr., Chellappa K., Silverman I.M., Quinn W.J., 3rd, Gosai S.J., Tichy E.D., Davis J.G., et al. Loss of NAD Homeostasis Leads to Progressive and Reversible Degeneration of Skeletal Muscle. Cell Metab. 2016;24:269&#x2013;282. doi: 10.1016/j.cmet.2016.07.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2016.07.005</ArticleId><ArticleId IdType="pmc">PMC4985182</ArticleId><ArticleId IdType="pubmed">27508874</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshino J., Mills K.F., Yoon M.J., Imai S. Nicotinamide mononucleotide, a key NAD+ intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 2011;14:528&#x2013;536. doi: 10.1016/j.cmet.2011.08.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2011.08.014</ArticleId><ArticleId IdType="pmc">PMC3204926</ArticleId><ArticleId IdType="pubmed">21982712</ArticleId></ArticleIdList></Reference><Reference><Citation>Araki T., Sasaki Y., Milbrandt J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science. 2004;305:1010&#x2013;1013. doi: 10.1126/science.1098014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1098014</ArticleId><ArticleId IdType="pubmed">15310905</ArticleId></ArticleIdList></Reference><Reference><Citation>Corpas R., Grinan-Ferre C., Rodriguez-Farre E., Pallas M., Sanfeliu C. Resveratrol Induces Brain Resilience against Alzheimer Neurodegeneration through Proteostasis Enhancement. Mol. Neurobiol. 2019;56:1502&#x2013;1516. doi: 10.1007/s12035-018-1157-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-1157-y</ArticleId><ArticleId IdType="pubmed">29948950</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W., Qian L., Zhang J., Zhang W., Morrison A., Hayes P., Wilson S., Chen T., Zhao J. Sirt1 overexpression in neurons promotes neurite outgrowth and cell survival through inhibition of the mTOR signaling. J. Neurosci. Res. 2011;89:1723&#x2013;1736. doi: 10.1002/jnr.22725.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.22725</ArticleId><ArticleId IdType="pubmed">21826702</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou X.D., Guo S.Q., Hu Z.W., Li W.L. NAMPT protects against 6-hydroxydopamine-induced neurotoxicity in PC12 cells through modulating SIRT1 activity. Mol. Med. Rep. 2016;13:4058&#x2013;4064. doi: 10.3892/mmr.2016.5034.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2016.5034</ArticleId><ArticleId IdType="pubmed">27035562</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe S., Ageta-Ishihara N., Nagatsu S., Takao K., Komine O., Endo F., Miyakawa T., Misawa H., Takahashi R., Kinoshita M., et al. SIRT1 overexpression ameliorates a mouse model of SOD1-linked amyotrophic lateral sclerosis via HSF1/HSP70i chaperone system. Mol. Brain. 2014;7:62. doi: 10.1186/s13041-014-0062-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13041-014-0062-1</ArticleId><ArticleId IdType="pmc">PMC4237944</ArticleId><ArticleId IdType="pubmed">25167838</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L.Q., Van Haandel L., Xiong M., Huang P., Heruth D.P., Bi C., Gaedigk R., Jiang X., Li D.Y., Wyckoff G., et al. Metabolic and molecular insights into an essential role of nicotinamide phosphoribosyltransferase. Cell Death Dis. 2017;8:e2705. doi: 10.1038/cddis.2017.132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2017.132</ArticleId><ArticleId IdType="pmc">PMC5386535</ArticleId><ArticleId IdType="pubmed">28333140</ArticleId></ArticleIdList></Reference><Reference><Citation>Mouchiroud L., Houtkooper R.H., Moullan N., Katsyuba E., Ryu D., Canto C., Mottis A., Jo Y.S., Viswanathan M., Schoonjans K., et al. The NAD+/Sirtuin Pathway Modulates Longevity through Activation of Mitochondrial UPR and FOXO Signaling. Cell. 2013;154:430&#x2013;441. doi: 10.1016/j.cell.2013.06.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2013.06.016</ArticleId><ArticleId IdType="pmc">PMC3753670</ArticleId><ArticleId IdType="pubmed">23870130</ArticleId></ArticleIdList></Reference><Reference><Citation>Roichman A., Elhanati S., Aon M.A., Abramovich I., Di Francesco A., Shahar Y., Avivi M.Y., Shurgi M., Rubinstein A., Wiesner Y., et al. Restoration of energy homeostasis by SIRT6 extends healthy lifespan. Nat. Commun. 2021;12:3208. doi: 10.1038/s41467-021-23545-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-23545-7</ArticleId><ArticleId IdType="pmc">PMC8163764</ArticleId><ArticleId IdType="pubmed">34050173</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai P., Canto C. The role of PARP-1 and PARP-2 enzymes in metabolic regulation and disease. Cell Metab. 2012;16:290&#x2013;295. doi: 10.1016/j.cmet.2012.06.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2012.06.016</ArticleId><ArticleId IdType="pubmed">22921416</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnakumar R., Kraus W.L. The PARP side of the nucleus: Molecular actions, physiological outcomes, and clinical targets. Mol. Cell. 2010;39:8&#x2013;24. doi: 10.1016/j.molcel.2010.06.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2010.06.017</ArticleId><ArticleId IdType="pmc">PMC2923840</ArticleId><ArticleId IdType="pubmed">20603072</ArticleId></ArticleIdList></Reference><Reference><Citation>Rongvaux A., Galli M., Denanglaire S., Van Gool F., Dreze P.L., Szpirer C., Bureau F., Andris F., Leo O. Nicotinamide phosphoribosyl transferase/pre-B cell colony-enhancing factor/visfatin is required for lymphocyte development and cellular resistance to genotoxic stress. J. Immunol. 2008;181:4685&#x2013;4695. doi: 10.4049/jimmunol.181.7.4685.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.181.7.4685</ArticleId><ArticleId IdType="pubmed">18802071</ArticleId></ArticleIdList></Reference><Reference><Citation>Alano C.C., Garnier P., Ying W., Higashi Y., Kauppinen T.M., Swanson R.A. NAD+ depletion is necessary and sufficient for poly(ADP-ribose) polymerase-1-mediated neuronal death. J. Neurosci. 2010;30:2967&#x2013;2978. doi: 10.1523/JNEUROSCI.5552-09.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5552-09.2010</ArticleId><ArticleId IdType="pmc">PMC2864043</ArticleId><ArticleId IdType="pubmed">20181594</ArticleId></ArticleIdList></Reference><Reference><Citation>Rappou E., Jukarainen S., Rinnankoski-Tuikka R., Kaye S., Heinonen S., Hakkarainen A., Lundbom J., Lundbom N., Saunavaara V., Rissanen A., et al. Weight Loss Is Associated With Increased NAD+/SIRT1 Expression But Reduced PARP Activity in White Adipose Tissue. J. Clin. Endocrinol. Metab. 2016;101:1263&#x2013;1273. doi: 10.1210/jc.2015-3054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2015-3054</ArticleId><ArticleId IdType="pubmed">26760174</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu D., Zhang H., Ropelle E.R., Sorrentino V., Mazala D.A., Mouchiroud L., Marshall P.L., Campbell M.D., Ali A.S., Knowels G.M., et al. NAD+ repletion improves muscle function in muscular dystrophy and counters global PARylation. Sci. Transl. Med. 2016;8:361ra139. doi: 10.1126/scitranslmed.aaf5504.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaf5504</ArticleId><ArticleId IdType="pmc">PMC5535761</ArticleId><ArticleId IdType="pubmed">27798264</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J.H., Long A., Owens K., Kristian T. Nicotinamide mononucleotide inhibits post-ischemic NAD+ degradation and dramatically ameliorates brain damage following global cerebral ischemia. Neurobiol. Dis. 2016;95:102&#x2013;110. doi: 10.1016/j.nbd.2016.07.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2016.07.018</ArticleId><ArticleId IdType="pmc">PMC5580241</ArticleId><ArticleId IdType="pubmed">27425894</ArticleId></ArticleIdList></Reference><Reference><Citation>Cameron A.M., Castoldi A., Sanin D.E., Flachsmann L.J., Field C.S., Puleston D.J., Kyle R.L., Patterson A.E., Hassler F., Buescher J.M., et al. Inflammatory macrophage dependence on NAD+ salvage is a consequence of reactive oxygen species-mediated DNA damage. Nat. Immunol. 2019;20:420&#x2013;432. doi: 10.1038/s41590-019-0336-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-019-0336-y</ArticleId><ArticleId IdType="pubmed">30858618</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilk A., Hayat F., Cunningham R., Li J., Garavaglia S., Zamani L., Ferraris D.M., Sykora P., Andrews J., Clark J., et al. Extracellular NAD+ enhances PARP-dependent DNA repair capacity independently of CD73 activity. Sci. Rep. 2020;10:651. doi: 10.1038/s41598-020-57506-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-57506-9</ArticleId><ArticleId IdType="pmc">PMC6971268</ArticleId><ArticleId IdType="pubmed">31959836</ArticleId></ArticleIdList></Reference><Reference><Citation>Aksoy P., White T.A., Thompson M., Chini E.N. Regulation of intracellular levels of NAD: A novel role for CD38. Biochem. Biophys. Res. Commun. 2006;345:1386&#x2013;1392. doi: 10.1016/j.bbrc.2006.05.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.05.042</ArticleId><ArticleId IdType="pubmed">16730329</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki Y., Vohra B.P.S., Lund F.E., Milbrandt J. Nicotinamide Mononucleotide Adenylyl Transferase-Mediated Axonal Protection Requires Enzymatic Activity But Not Increased Levels of Neuronal Nicotinamide Adenine Dinucleotide. J. Neurosci. 2009;29:5525&#x2013;5535. doi: 10.1523/JNEUROSCI.5469-08.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5469-08.2009</ArticleId><ArticleId IdType="pmc">PMC3162248</ArticleId><ArticleId IdType="pubmed">19403820</ArticleId></ArticleIdList></Reference><Reference><Citation>Camacho-Pereira J., Tarrago M.G., Chini C.C.S., Nin V., Escande C., Warner G.M., Puranik A.S., Schoon R.A., Reid J.M., Galina A., et al. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell Metab. 2016;23:1127&#x2013;1139. doi: 10.1016/j.cmet.2016.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2016.05.006</ArticleId><ArticleId IdType="pmc">PMC4911708</ArticleId><ArticleId IdType="pubmed">27304511</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy A., Bercovich-Kinori A., Alexandrovich A.G., Tsenter J., Trembovler V., Lund F.E., Shohami E., Stein R., Mayo L. CD38 facilitates recovery from traumatic brain injury. J. Neurotrauma. 2009;26:1521&#x2013;1533. doi: 10.1089/neu.2008.0746.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/neu.2008.0746</ArticleId><ArticleId IdType="pmc">PMC2864472</ArticleId><ArticleId IdType="pubmed">19257806</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayakawa K., Esposito E., Wang X., Terasaki Y., Liu Y., Xing C., Ji X., Lo E.H. Transfer of mitochondria from astrocytes to neurons after stroke. Nature. 2016;535:551&#x2013;555. doi: 10.1038/nature18928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature18928</ArticleId><ArticleId IdType="pmc">PMC4968589</ArticleId><ArticleId IdType="pubmed">27466127</ArticleId></ArticleIdList></Reference><Reference><Citation>Long A., Park J.H., Klimova N., Fowler C., Loane D.J., Kristian T. CD38 Knockout Mice Show Significant Protection against Ischemic Brain Damage Despite High Level Poly-ADP-Ribosylation. Neurochem. Res. 2017;42:283&#x2013;293. doi: 10.1007/s11064-016-2031-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-016-2031-9</ArticleId><ArticleId IdType="pmc">PMC5580240</ArticleId><ArticleId IdType="pubmed">27518087</ArticleId></ArticleIdList></Reference><Reference><Citation>Essuman K., Summers D.W., Sasaki Y., Mao X., DiAntonio A., Milbrandt J. The SARM1 Toll/Interleukin-1 Receptor Domain Possesses Intrinsic NAD+ Cleavage Activity that Promotes Pathological Axonal Degeneration. Neuron. 2017;93:1334&#x2013;1343. doi: 10.1016/j.neuron.2017.02.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.02.022</ArticleId><ArticleId IdType="pmc">PMC6284238</ArticleId><ArticleId IdType="pubmed">28334607</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan L., Essuman K., Anderson R.G., Sasaki Y., Monteiro F., Chung E.H., Osborne Nishimura E., DiAntonio A., Milbrandt J., Dangl J.L., et al. TIR domains of plant immune receptors are NAD+-cleaving enzymes that promote cell death. Science. 2019;365:799&#x2013;803. doi: 10.1126/science.aax1771.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aax1771</ArticleId><ArticleId IdType="pmc">PMC7045805</ArticleId><ArticleId IdType="pubmed">31439793</ArticleId></ArticleIdList></Reference><Reference><Citation>Horsefield S., Burdett H., Zhang X., Manik M.K., Shi Y., Chen J., Qi T., Gilley J., Lai J.S., Rank M.X., et al. NAD+ cleavage activity by animal and plant TIR domains in cell death pathways. Science. 2019;365:793&#x2013;799. doi: 10.1126/science.aax1911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aax1911</ArticleId><ArticleId IdType="pubmed">31439792</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki Y., Nakagawa T., Mao X., DiAntonio A., Milbrandt J. NMNAT1 inhibits axon degeneration via blockade of SARM1-mediated NAD+ depletion. Elife. 2016;5:e19749. doi: 10.7554/eLife.19749.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.19749</ArticleId><ArticleId IdType="pmc">PMC5063586</ArticleId><ArticleId IdType="pubmed">27735788</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilley J., Ribchester R.R., Coleman M.P. Sarm1 Deletion, but Not WldS, Confers Lifelong Rescue in a Mouse Model of Severe Axonopathy. Cell Rep. 2017;21:10&#x2013;16. doi: 10.1016/j.celrep.2017.09.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.09.027</ArticleId><ArticleId IdType="pmc">PMC5640801</ArticleId><ArticleId IdType="pubmed">28978465</ArticleId></ArticleIdList></Reference><Reference><Citation>Loreto A., Hill C.S., Hewitt V.L., Orsomando G., Angeletti C., Gilley J., Lucci C., Sanchez-Martinez A., Whitworth A.J., Conforti L., et al. Mitochondrial impairment activates the Wallerian pathway through depletion of NMNAT2 leading to SARM1-dependent axon degeneration. Neurobiol. Dis. 2020;134:104678. doi: 10.1016/j.nbd.2019.104678.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2019.104678</ArticleId><ArticleId IdType="pmc">PMC7611775</ArticleId><ArticleId IdType="pubmed">31740269</ArticleId></ArticleIdList></Reference><Reference><Citation>Figley M.D., Gu W., Nanson J.D., Shi Y., Sasaki Y., Cunnea K., Malde A.K., Jia X., Luo Z., Saikot F.K., et al. SARM1 is a metabolic sensor activated by an increased NMN/NAD+ ratio to trigger axon degeneration. Neuron. 2021;109:1118&#x2013;1136. doi: 10.1016/j.neuron.2021.02.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2021.02.009</ArticleId><ArticleId IdType="pmc">PMC8174188</ArticleId><ArticleId IdType="pubmed">33657413</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki Y., Zhu J., Shi Y., Gu W., Kobe B., Ve T., DiAntonio A., Milbrandt J. Nicotinic acid mononucleotide is an allosteric SARM1 inhibitor promoting axonal protection. Exp. Neurol. 2021;345:113842. doi: 10.1016/j.expneurol.2021.113842.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2021.113842</ArticleId><ArticleId IdType="pmc">PMC8571713</ArticleId><ArticleId IdType="pubmed">34403688</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloom A.J., Mao X., Strickland A., Sasaki Y., Milbrandt J., DiAntonio A. Constitutively active SARM1 variants found in ALS patients induce neuropathy. bioRxiv. 2021 doi: 10.1101/2021.04.16.439886.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.04.16.439886</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilley J., Jackson O., Pipis M., Estiar M.A., Gan-Or Z., Goutman S.A., Harms M.B., Kaye J., Lima L., Genomics Q.S., et al. Enrichment of SARM1 alleles encoding variants with constitutively hyperactive NADase in patients with ALS and other motor nerve disorders. medRxiv. 2021 doi: 10.1101/2021.06.17.21258268.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.17.21258268</ArticleId><ArticleId IdType="pubmed">34796871</ArticleId></ArticleIdList></Reference><Reference><Citation>Hopkins E.L., Gu W., Kobe B., Coleman M.P. A Novel NAD Signaling Mechanism in Axon Degeneration and its Relationship to Innate Immunity. Front. Mol. Biosci. 2021;8:703532. doi: 10.3389/fmolb.2021.703532.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2021.703532</ArticleId><ArticleId IdType="pmc">PMC8295901</ArticleId><ArticleId IdType="pubmed">34307460</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandya V.A., Patani R. Decoding the relationship between ageing and amyotrophic lateral sclerosis: A cellular perspective. Brain. 2020;143:1057&#x2013;1072. doi: 10.1093/brain/awz360.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz360</ArticleId><ArticleId IdType="pmc">PMC7174045</ArticleId><ArticleId IdType="pubmed">31851317</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappello V., Francolini M. Neuromuscular Junction Dismantling in Amyotrophic Lateral Sclerosis. Int. J. Mol. Sci. 2017;18:2092. doi: 10.3390/ijms18102092.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms18102092</ArticleId><ArticleId IdType="pmc">PMC5666774</ArticleId><ArticleId IdType="pubmed">28972545</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor J.P., Brown R.H., Jr., Cleveland D.W. Decoding ALS: From genes to mechanism. Nature. 2016;539:197&#x2013;206. doi: 10.1038/nature20413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20413</ArticleId><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Guillemin G.J. Kynurenine pathway metabolites in humans: Disease and healthy States. Int. J. Tryptophan Res. 2009;2:1&#x2013;19. doi: 10.4137/IJTR.S2097.</Citation><ArticleIdList><ArticleId IdType="doi">10.4137/IJTR.S2097</ArticleId><ArticleId IdType="pmc">PMC3195227</ArticleId><ArticleId IdType="pubmed">22084578</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacher E., Bashiardes S., Shapiro H., Rothschild D., Mor U., Dori-Bachash M., Kleimeyer C., Moresi C., Harnik Y., Zur M., et al. Potential roles of gut microbiome and metabolites in modulating ALS in mice. Nature. 2019;572:474&#x2013;480. doi: 10.1038/s41586-019-1443-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1443-5</ArticleId><ArticleId IdType="pubmed">31330533</ArticleId></ArticleIdList></Reference><Reference><Citation>Roderer P., Klatt L., John F., Theis V., Winklhofer K.F., Theiss C., Matschke V. Increased ROS Level in Spinal Cord of Wobbler Mice due to Nmnat2 Downregulation. Mol. Neurobiol. 2018;55:8414&#x2013;8424. doi: 10.1007/s12035-018-0999-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-0999-7</ArticleId><ArticleId IdType="pubmed">29549647</ArticleId></ArticleIdList></Reference><Reference><Citation>Obrador E., Salvador R., Marchio P., Lopez-Blanch R., Jihad-Jebbar A., Rivera P., Valles S.L., Banacloche S., Alcacer J., Colomer N., et al. Nicotinamide Riboside and Pterostilbene Cooperatively Delay Motor Neuron Failure in ALS SOD1G93A Mice. Mol. Neurobiol. 2021;58:1345&#x2013;1371. doi: 10.1007/s12035-020-02188-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-020-02188-7</ArticleId><ArticleId IdType="pubmed">33174130</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundt S., Zhang N., Wang X., Polo-Parada L., Ding S. The effect of NAMPT deletion in projection neurons on the function and structure of neuromuscular junction (NMJ) in mice. Sci. Rep. 2020;10:99. doi: 10.1038/s41598-019-57085-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-57085-4</ArticleId><ArticleId IdType="pmc">PMC6952356</ArticleId><ArticleId IdType="pubmed">31919382</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesla R., Wolf H.P., Xu P., Drawbridge J., Estill S.J., Huntington P., McDaniel L., Knobbe W., Burket A., Tran S., et al. Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA. 2012;109:17016&#x2013;17021. doi: 10.1073/pnas.1213960109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1213960109</ArticleId><ArticleId IdType="pmc">PMC3479516</ArticleId><ArticleId IdType="pubmed">23027932</ArticleId></ArticleIdList></Reference><Reference><Citation>Harlan B.A., Killoy K.M., Pehar M., Liu L., Auwerx J., Vargas M.R. Evaluation of the NAD+ biosynthetic pathway in ALS patients and effect of modulating NAD+ levels in hSOD1-linked ALS mouse models. Exp. Neurol. 2020;327:113219. doi: 10.1016/j.expneurol.2020.113219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2020.113219</ArticleId><ArticleId IdType="pmc">PMC7089832</ArticleId><ArticleId IdType="pubmed">32014438</ArticleId></ArticleIdList></Reference><Reference><Citation>Zwilling M., Theiss C., Matschke V. Caffeine and NAD+ Improve Motor Neural Integrity of Dissociated Wobbler Cells in vitro. Antioxidants. 2020;9:460. doi: 10.3390/antiox9060460.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox9060460</ArticleId><ArticleId IdType="pmc">PMC7346375</ArticleId><ArticleId IdType="pubmed">32471290</ArticleId></ArticleIdList></Reference><Reference><Citation>Hor J.H., Santosa M.M., Lim V.J.W., Ho B.X., Taylor A., Khong Z.J., Ravits J., Fan Y., Liou Y.C., Soh B.S., et al. ALS motor neurons exhibit hallmark metabolic defects that are rescued by SIRT3 activation. Cell Death Differ. 2021;28:1379&#x2013;1397. doi: 10.1038/s41418-020-00664-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-020-00664-0</ArticleId><ArticleId IdType="pmc">PMC8027637</ArticleId><ArticleId IdType="pubmed">33184465</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q., Zhu L., Qiu W., Liu Y., Yang F., Chen W., Xu R. Nicotinamide Riboside Enhances Mitochondrial Proteostasis and Adult Neurogenesis through Activation of Mitochondrial Unfolded Protein Response Signaling in the Brain of ALS SOD1G93A Mice. Int. J. Biol. Sci. 2020;16:284&#x2013;297. doi: 10.7150/ijbs.38487.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.38487</ArticleId><ArticleId IdType="pmc">PMC6949147</ArticleId><ArticleId IdType="pubmed">31929756</ArticleId></ArticleIdList></Reference><Reference><Citation>Harlan B.A., Pehar M., Killoy K.M., Vargas M.R. Enhanced SIRT6 activity abrogates the neurotoxic phenotype of astrocytes expressing ALS-linked mutant SOD1. FASEB J. 2019;33:7084&#x2013;7091. doi: 10.1096/fj.201802752R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201802752R</ArticleId><ArticleId IdType="pmc">PMC6529338</ArticleId><ArticleId IdType="pubmed">30841754</ArticleId></ArticleIdList></Reference><Reference><Citation>Harlan B.A., Pehar M., Sharma D.R., Beeson G., Beeson C.C., Vargas M.R. Enhancing NAD+ Salvage Pathway Reverts the Toxicity of Primary Astrocytes Expressing Amyotrophic Lateral Sclerosis-linked Mutant Superoxide Dismutase 1 (SOD1) J. Biol. Chem. 2016;291:10836&#x2013;10846. doi: 10.1074/jbc.M115.698779.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.698779</ArticleId><ArticleId IdType="pmc">PMC4865928</ArticleId><ArticleId IdType="pubmed">27002158</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R., del Valle J., Modol L., Martinez A., Granado-Serrano A.B., Ramirez-Nunez O., Pallas M., Portero-Otin M., Osta R., Navarro X. Resveratrol improves motoneuron function and extends survival in SOD1G93A ALS mice. Neurotherapeutics. 2014;11:419&#x2013;432. doi: 10.1007/s13311-013-0253-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-013-0253-y</ArticleId><ArticleId IdType="pmc">PMC3996124</ArticleId><ArticleId IdType="pubmed">24414863</ArticleId></ArticleIdList></Reference><Reference><Citation>Herskovits A.Z., Hunter T.A., Maxwell N., Pereira K., Whittaker C.A., Valdez G., Guarente L.P. SIRT1 deacetylase in aging-induced neuromuscular degeneration and amyotrophic lateral sclerosis. Aging Cell. 2018;17:e12839. doi: 10.1111/acel.12839.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.12839</ArticleId><ArticleId IdType="pmc">PMC6260920</ArticleId><ArticleId IdType="pubmed">30295421</ArticleId></ArticleIdList></Reference><Reference><Citation>Buck E., Bayer H., Lindenberg K.S., Hanselmann J., Pasquarelli N., Ludolph A.C., Weydt P., Witting A. Comparison of Sirtuin 3 Levels in ALS and Huntington&#x2019;s Disease-Differential Effects in Human Tissue Samples vs. Transgenic Mouse Models. Front. Mol. Neurosci. 2017;10:156. doi: 10.3389/fnmol.2017.00156.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00156</ArticleId><ArticleId IdType="pmc">PMC5445120</ArticleId><ArticleId IdType="pubmed">28603486</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown D.G., Shorter J., Wobst H.J. Emerging small-molecule therapeutic approaches for amyotrophic lateral sclerosis and frontotemporal dementia. Bioorg. Med. Chem. Lett. 2020;30:126942. doi: 10.1016/j.bmcl.2019.126942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2019.126942</ArticleId><ArticleId IdType="pubmed">31926785</ArticleId></ArticleIdList></Reference><Reference><Citation>McGurk L., Mojsilovic-Petrovic J., Van Deerlin V.M., Shorter J., Kalb R.G., Lee V.M., Trojanowski J.Q., Lee E.B., Bonini N.M. Nuclear poly(ADP-ribose) activity is a therapeutic target in amyotrophic lateral sclerosis. Acta Neuropathol. Commun. 2018;6:84. doi: 10.1186/s40478-018-0586-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-018-0586-1</ArticleId><ArticleId IdType="pmc">PMC6114235</ArticleId><ArticleId IdType="pubmed">30157956</ArticleId></ArticleIdList></Reference><Reference><Citation>Veriepe J., Fossouo L., Parker J.A. Neurodegeneration in C. elegans models of ALS requires TIR-1/Sarm1 immune pathway activation in neurons. Nat. Commun. 2015;6:7319. doi: 10.1038/ncomms8319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms8319</ArticleId><ArticleId IdType="pubmed">26059317</ArticleId></ArticleIdList></Reference><Reference><Citation>White M.A., Lin Z., Kim E., Henstridge C.M., Pena Altamira E., Hunt C.K., Burchill E., Callaghan I., Loreto A., Brown-Wright H., et al. Sarm1 deletion suppresses TDP-43-linked motor neuron degeneration and cortical spine loss. Acta Neuropathol. Commun. 2019;7:166. doi: 10.1186/s40478-019-0800-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-019-0800-9</ArticleId><ArticleId IdType="pmc">PMC6819591</ArticleId><ArticleId IdType="pubmed">31661035</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters O.M., Lewis E.A., Osterloh J.M., Weiss A., Salameh J.S., Metterville J., Brown R.H., Freeman M.R. Loss of Sarm1 does not suppress motor neuron degeneration in the SOD1G93A mouse model of amyotrophic lateral sclerosis. Hum. Mol. Genet. 2018;27:3761&#x2013;3771. doi: 10.1093/hmg/ddy260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddy260</ArticleId><ArticleId IdType="pmc">PMC6196650</ArticleId><ArticleId IdType="pubmed">30010873</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Rubia J.E., Drehmer E., Platero J.L., Benlloch M., Caplliure-Llopis J., Villaron-Casales C., de Bernardo N., AlarcOn J., Fuente C., Carrera S., et al. Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: A randomized, double-blind, placebo-controlled human pilot study. Amyotroph. Lateral Scler. Front. Degener. 2019;20:115&#x2013;122. doi: 10.1080/21678421.2018.1536152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1536152</ArticleId><ArticleId IdType="pubmed">30668199</ArticleId></ArticleIdList></Reference><Reference><Citation>Stavrou M., Sargiannidou I., Georgiou E., Kagiava A., Kleopa K.A. Emerging Therapies for Charcot-Marie-Tooth Inherited Neuropathies. Int. J. Mol. Sci. 2021;22:6048. doi: 10.3390/ijms22116048.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22116048</ArticleId><ArticleId IdType="pmc">PMC8199910</ArticleId><ArticleId IdType="pubmed">34205075</ArticleId></ArticleIdList></Reference><Reference><Citation>Moss K.R., Hoke A. Targeting the programmed axon degeneration pathway as a potential therapeutic for Charcot-Marie-Tooth disease. Brain Res. 2020;1727:146539. doi: 10.1016/j.brainres.2019.146539.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2019.146539</ArticleId><ArticleId IdType="pmc">PMC6939145</ArticleId><ArticleId IdType="pubmed">31689415</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman M.R. Signaling mechanisms regulating Wallerian degeneration. Curr. Opin. Neurobiol. 2014;27:224&#x2013;231. doi: 10.1016/j.conb.2014.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conb.2014.05.001</ArticleId><ArticleId IdType="pmc">PMC4122608</ArticleId><ArticleId IdType="pubmed">24907513</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer zu Horste G., Miesbach T.A., Muller J.I., Fledrich R., Stassart R.M., Kieseier B.C., Coleman M.P., Sereda M.W. The Wlds transgene reduces axon loss in a Charcot-Marie-Tooth disease 1A rat model and nicotinamide delays post-traumatic axonal degeneration. Neurobiol. Dis. 2011;42:1&#x2013;8. doi: 10.1016/j.nbd.2010.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2010.12.006</ArticleId><ArticleId IdType="pubmed">21168501</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu W.Y., Gu M.M., Sun L.H., Guo W.T., Zhu H.B., Ma J.F., Yuan W.T., Kuang Y., Ji B.J., Wu X.L., et al. A nonsense mutation in DHTKD1 causes Charcot-Marie-Tooth disease type 2 in a large Chinese pedigree. Am. J. Hum. Genet. 2012;91:1088&#x2013;1094. doi: 10.1016/j.ajhg.2012.09.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2012.09.018</ArticleId><ArticleId IdType="pmc">PMC3516600</ArticleId><ArticleId IdType="pubmed">23141294</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolino A., Piguet F., Alberizzi V., Pellegatta M., Rivellini C., Guerrero-Valero M., Noseda R., Brombin C., Nonis A., D&#x2019;Adamo P., et al. Niacin-mediated Tace activation ameliorates CMT neuropathies with focal hypermyelination. EMBO Mol. Med. 2016;8:1438&#x2013;1454. doi: 10.15252/emmm.201606349.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201606349</ArticleId><ArticleId IdType="pmc">PMC5167133</ArticleId><ArticleId IdType="pubmed">27799291</ArticleId></ArticleIdList></Reference><Reference><Citation>Cassereau J., Chevrollier A., Codron P., Goizet C., Gueguen N., Verny C., Reynier P., Bonneau D., Lenaers G., Procaccio V. Oxidative stress contributes differentially to the pathophysiology of Charcot-Marie-Tooth disease type 2K. Exp. Neurol. 2020;323:113069. doi: 10.1016/j.expneurol.2019.113069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2019.113069</ArticleId><ArticleId IdType="pubmed">31655048</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y., Xie L., Shen C., Qi Q., Qin Y., Xing J., Zhou D., Qi Y., Yan Z., Lin X., et al. SIRT2-knockdown rescues GARS-induced Charcot-Marie-Tooth neuropathy. Aging Cell. 2021;20:e13391. doi: 10.1111/acel.13391.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.13391</ArticleId><ArticleId IdType="pmc">PMC8208790</ArticleId><ArticleId IdType="pubmed">34053152</ArticleId></ArticleIdList></Reference><Reference><Citation>Chini C.C.S., Zeidler J.D., Kashyap S., Warner G., Chini E.N. Evolving concepts in NAD+ metabolism. Cell Metab. 2021;33:1076&#x2013;1087. doi: 10.1016/j.cmet.2021.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2021.04.003</ArticleId><ArticleId IdType="pmc">PMC8172449</ArticleId><ArticleId IdType="pubmed">33930322</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes M.T. Parkinson&#x2019;s Disease and Parkinsonism. Am. J. Med. 2019;132:802&#x2013;807. doi: 10.1016/j.amjmed.2019.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2019.03.001</ArticleId><ArticleId IdType="pubmed">30890425</ArticleId></ArticleIdList></Reference><Reference><Citation>Thirtamara-Rajamani K., Li P., Escobar Galvis M.L., Labrie V., Brundin P., Brundin L. Is the Enzyme ACMSD a Novel Therapeutic Target in Parkinson&#x2019;s Disease? J. Parkinsons Dis. 2017;7:577&#x2013;587. doi: 10.3233/JPD-171240.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JPD-171240</ArticleId><ArticleId IdType="pmc">PMC5676848</ArticleId><ArticleId IdType="pubmed">29103054</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy P.J., Cryan J.F., Dinan T.G., Clarke G. Kynurenine pathway metabolism and the microbiota-gut-brain axis. Neuropharmacology. 2017;112:399&#x2013;412. doi: 10.1016/j.neuropharm.2016.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2016.07.002</ArticleId><ArticleId IdType="pubmed">27392632</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mahony S.M., Clarke G., Borre Y.E., Dinan T.G., Cryan J.F. Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. Behav. Brain Res. 2015;277:32&#x2013;48. doi: 10.1016/j.bbr.2014.07.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2014.07.027</ArticleId><ArticleId IdType="pubmed">25078296</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatesan D., Iyer M., Narayanasamy A., Siva K., Vellingiri B. Kynurenine pathway in Parkinson&#x2019;s disease-An update. Eneurologicalsci. 2020;21:100270. doi: 10.1016/j.ensci.2020.100270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ensci.2020.100270</ArticleId><ArticleId IdType="pmc">PMC7585940</ArticleId><ArticleId IdType="pubmed">33134567</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwab A.J., Sison S.L., Meade M.R., Broniowska K.A., Corbett J.A., Ebert A.D. Decreased Sirtuin Deacetylase Activity in LRRK2 G2019S iPSC-Derived Dopaminergic Neurons. Stem Cell Rep. 2017;9:1839&#x2013;1852. doi: 10.1016/j.stemcr.2017.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2017.10.010</ArticleId><ArticleId IdType="pmc">PMC5785678</ArticleId><ArticleId IdType="pubmed">29129681</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu L., Tang L., Wei W., Hong Y., Chen H., Ying W., Chen S. Nicotinamide mononucleotide improves energy activity and survival rate in an in vitro model of Parkinson&#x2019;s disease. Exp. Ther. Med. 2014;8:943&#x2013;950. doi: 10.3892/etm.2014.1842.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2014.1842</ArticleId><ArticleId IdType="pmc">PMC4113526</ArticleId><ArticleId IdType="pubmed">25120628</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheline C.T., Zhu J., Zhang W., Shi C., Cai A.L. Mitochondrial inhibitor models of Huntington&#x2019;s disease and Parkinson&#x2019;s disease induce zinc accumulation and are attenuated by inhibition of zinc neurotoxicity in vitro or in vivo. Neurodegener. Dis. 2013;11:49&#x2013;58. doi: 10.1159/000336558.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000336558</ArticleId><ArticleId IdType="pubmed">22627004</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia H., Li X., Gao H., Feng Z., Li X., Zhao L., Jia X., Zhang H., Liu J. High doses of nicotinamide prevent oxidative mitochondrial dysfunction in a cellular model and improve motor deficit in a Drosophila model of Parkinson&#x2019;s disease. J. Neurosci. Res. 2008;86:2083&#x2013;2090. doi: 10.1002/jnr.21650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.21650</ArticleId><ArticleId IdType="pubmed">18381761</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmann S., Costa A.C., Celardo I., Loh S.H., Martins L.M. Parp mutations protect against mitochondrial dysfunction and neurodegeneration in a PARKIN model of Parkinson&#x2019;s disease. Cell Death Dis. 2016;7:e2166. doi: 10.1038/cddis.2016.72.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2016.72</ArticleId><ArticleId IdType="pmc">PMC4823968</ArticleId><ArticleId IdType="pubmed">27031963</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmann S., Loh S.H., Martins L.M. Enhancing NAD+ salvage metabolism is neuroprotective in a PINK1 model of Parkinson&#x2019;s disease. Biol. Open. 2017;6:141&#x2013;147. doi: 10.1242/bio.022186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/bio.022186</ArticleId><ArticleId IdType="pmc">PMC5312101</ArticleId><ArticleId IdType="pubmed">28011627</ArticleId></ArticleIdList></Reference><Reference><Citation>Schondorf D.C., Ivanyuk D., Baden P., Sanchez-Martinez A., De Cicco S., Yu C., Giunta I., Schwarz L.K., Di Napoli G., Panagiotakopoulou V., et al. The NAD+ Precursor Nicotinamide Riboside Rescues Mitochondrial Defects and Neuronal Loss in iPSC and Fly Models of Parkinson&#x2019;s Disease. Cell Rep. 2018;23:2976&#x2013;2988. doi: 10.1016/j.celrep.2018.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2018.05.009</ArticleId><ArticleId IdType="pubmed">29874584</ArticleId></ArticleIdList></Reference><Reference><Citation>Shan C., Gong Y.L., Zhuang Q.Q., Hou Y.F., Wang S.M., Zhu Q., Huang G.R., Tao B., Sun L.H., Zhao H.Y., et al. Protective effects of &#x3b2;- nicotinamide adenine dinucleotide against motor deficits and dopaminergic neuronal damage in a mouse model of Parkinson&#x2019;s disease. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2019;94:109670. doi: 10.1016/j.pnpbp.2019.109670.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pnpbp.2019.109670</ArticleId><ArticleId IdType="pubmed">31220519</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jesus-Cortes H., Xu P., Drawbridge J., Estill S.J., Huntington P., Tran S., Britt J., Tesla R., Morlock L., Naidoo J., et al. Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of Parkinson disease. Proc. Natl. Acad. Sci. USA. 2012;109:17010&#x2013;17015. doi: 10.1073/pnas.1213956109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1213956109</ArticleId><ArticleId IdType="pmc">PMC3479520</ArticleId><ArticleId IdType="pubmed">23027934</ArticleId></ArticleIdList></Reference><Reference><Citation>Naidoo J., De Jesus-Cortes H., Huntington P., Estill S., Morlock L.K., Starwalt R., Mangano T.J., Williams N.S., Pieper A.A., Ready J.M. Discovery of a neuroprotective chemical, (S)-N-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-fluoropropyl)-6-methoxypyridin-2-amine [(-)-P7C3-S243], with improved druglike properties. J. Med. Chem. 2014;57:3746&#x2013;3754. doi: 10.1021/jm401919s.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm401919s</ArticleId><ArticleId IdType="pmc">PMC4206694</ArticleId><ArticleId IdType="pubmed">24697290</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jesus-Cortes H., Miller A.D., Britt J.K., DeMarco A.J., De Jesus-Cortes M., Stuebing E., Naidoo J., Vazquez-Rosa E., Morlock L., Williams N.S., et al. Protective efficacy of P7C3-S243 in the 6-hydroxydopamine model of Parkinson&#x2019;s disease. NPJ Parkinsons Dis. 2015;1:15010. doi: 10.1038/npjparkd.2015.10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/npjparkd.2015.10</ArticleId><ArticleId IdType="pmc">PMC4859442</ArticleId><ArticleId IdType="pubmed">27158662</ArticleId></ArticleIdList></Reference><Reference><Citation>Santiago J.A., Littlefield A.M., Potashkin J.A. Integrative transcriptomic meta-analysis of Parkinson&#x2019;s disease and depression identifies NAMPT as a potential blood biomarker for de novo Parkinson&#x2019;s disease. Sci. Rep. 2016;6:34579. doi: 10.1038/srep34579.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep34579</ArticleId><ArticleId IdType="pmc">PMC5041099</ArticleId><ArticleId IdType="pubmed">27680512</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Y., Wu Q., Shi J., Zhou S. Regulation of SIRT3 on mitochondrial functions and oxidative stress in Parkinson&#x2019;s disease. Biomed. Pharmacother. 2020;132:110928. doi: 10.1016/j.biopha.2020.110928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2020.110928</ArticleId><ArticleId IdType="pubmed">33128944</ArticleId></ArticleIdList></Reference><Reference><Citation>Maszlag-Torok R., Boros F.A., Vecsei L., Klivenyi P. Gene variants and expression changes of SIRT1 and SIRT6 in peripheral blood are associated with Parkinson&#x2019;s disease. Sci. Rep. 2021;11:10677. doi: 10.1038/s41598-021-90059-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-90059-z</ArticleId><ArticleId IdType="pmc">PMC8140123</ArticleId><ArticleId IdType="pubmed">34021216</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Liu T., Wu T.T., Feng Y., Peng S.J., Yin H., Wu Y.C. SIRT1 Deacetylates TET2 and Promotes Its Ubiquitination Degradation to Achieve Neuroprotection Against Parkinson&#x2019;s Disease. Front. Neurol. 2021;12:652882. doi: 10.3389/fneur.2021.652882.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2021.652882</ArticleId><ArticleId IdType="pmc">PMC8082066</ArticleId><ArticleId IdType="pubmed">33935952</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z.D., Tan E.K. Oxidized nicotinamide adenine dinucleotide-dependent mitochondrial deacetylase sirtuin-3 as a potential therapeutic target of Parkinson&#x2019;s disease. Ageing Res. Rev. 2020;62:101107. doi: 10.1016/j.arr.2020.101107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2020.101107</ArticleId><ArticleId IdType="pubmed">32535274</ArticleId></ArticleIdList></Reference><Reference><Citation>Thapa K., Khan H., Sharma U., Grewal A.K., Singh T.G. Poly (ADP-ribose) polymerase-1 as a promising drug target for neurodegenerative diseases. Life Sci. 2021;267:118975. doi: 10.1016/j.lfs.2020.118975.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2020.118975</ArticleId><ArticleId IdType="pubmed">33387580</ArticleId></ArticleIdList></Reference><Reference><Citation>Salemi M., Mazzetti S., De Leonardis M., Giampietro F., Medici V., Poloni T.E., Cannarella R., Giaccone G., Pezzoli G., Cappelletti G., et al. Poly (ADP-ribose) polymerase 1 and Parkinson&#x2019;s disease: A study in post-mortem human brain. Neurochem. Int. 2021;144:104978. doi: 10.1016/j.neuint.2021.104978.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2021.104978</ArticleId><ArticleId IdType="pubmed">33516746</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakade C., Chong R., Bradley E., Morgan J.C. Low-dose niacin supplementation modulates GPR109A, niacin index and ameliorates Parkinson&#x2019;s disease symptoms without side effects. Clin. Case Rep. 2015;3:635&#x2013;637. doi: 10.1002/ccr3.232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccr3.232</ArticleId><ArticleId IdType="pmc">PMC4527813</ArticleId><ArticleId IdType="pubmed">26273459</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong R., Wakade C., Seamon M., Giri B., Morgan J., Purohit S. Niacin Enhancement for Parkinson&#x2019;s Disease: An Effectiveness Trial. Front. Aging Neurosci. 2021;13:667032. doi: 10.3389/fnagi.2021.667032.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2021.667032</ArticleId><ArticleId IdType="pmc">PMC8245760</ArticleId><ArticleId IdType="pubmed">34220485</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoker T.B., Mason S.L., Greenland J.C., Holden S.T., Santini H., Barker R.A. Huntington&#x2019;s disease: Diagnosis and management. Pract. Neurol. 2021 doi: 10.1136/practneurol-2021-003074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/practneurol-2021-003074</ArticleId><ArticleId IdType="pubmed">34413240</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim A., Lalonde K., Truesdell A., Gomes Welter P., Brocardo P.S., Rosenstock T.R., Gil-Mohapel J. New Avenues for the Treatment of Huntington&#x2019;s Disease. Int. J. Mol. Sci. 2021;22:8363. doi: 10.3390/ijms22168363.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22168363</ArticleId><ArticleId IdType="pmc">PMC8394361</ArticleId><ArticleId IdType="pubmed">34445070</ArticleId></ArticleIdList></Reference><Reference><Citation>McGarry A., Gaughan J., Hackmyer C., Lovett J., Khadeer M., Shaikh H., Pradhan B., Ferraro T.N., Wainer I.W., Moaddel R. Cross-sectional analysis of plasma and CSF metabolomic markers in Huntington&#x2019;s disease for participants of varying functional disability: A pilot study. Sci. Rep. 2020;10:20490. doi: 10.1038/s41598-020-77526-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-77526-9</ArticleId><ArticleId IdType="pmc">PMC7686309</ArticleId><ArticleId IdType="pubmed">33235276</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh V., Sharma R.K., Athilingam T., Sinha P., Sinha N., Thakur A.K. NMR Spectroscopy-based Metabolomics of Drosophila Model of Huntington&#x2019;s Disease Suggests Altered Cell Energetics. J. Proteome Res. 2017;16:3863&#x2013;3872. doi: 10.1021/acs.jproteome.7b00491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.7b00491</ArticleId><ArticleId IdType="pubmed">28871787</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertrand M., Decoville M., Meudal H., Birman S., Landon C. Metabolomic Nuclear Magnetic Resonance Studies at Presymptomatic and Symptomatic Stages of Huntington&#x2019;s Disease on a Drosophila Model. J. Proteome Res. 2020;19:4034&#x2013;4045. doi: 10.1021/acs.jproteome.0c00335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.0c00335</ArticleId><ArticleId IdType="pubmed">32880177</ArticleId></ArticleIdList></Reference><Reference><Citation>Pallos J., Bodai L., Lukacsovich T., Purcell J.M., Steffan J.S., Thompson L.M., Marsh J.L. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington&#x2019;s disease. Hum. Mol. Genet. 2008;17:3767&#x2013;3775. doi: 10.1093/hmg/ddn273.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddn273</ArticleId><ArticleId IdType="pmc">PMC2581431</ArticleId><ArticleId IdType="pubmed">18762557</ArticleId></ArticleIdList></Reference><Reference><Citation>Hathorn T., Snyder-Keller A., Messer A. Nicotinamide improves motor deficits and upregulates PGC-1&#x3b1; and BDNF gene expression in a mouse model of Huntington&#x2019;s disease. Neurobiol. Dis. 2011;41:43&#x2013;50. doi: 10.1016/j.nbd.2010.08.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2010.08.017</ArticleId><ArticleId IdType="pmc">PMC2996046</ArticleId><ArticleId IdType="pubmed">20736066</ArticleId></ArticleIdList></Reference><Reference><Citation>Naia L., Rosenstock T.R., Oliveira A.M., Oliveira-Sousa S.I., Caldeira G.L., Carmo C., Laco M.N., Hayden M.R., Oliveira C.R., Rego A.C. Comparative Mitochondrial-Based Protective Effects of Resveratrol and Nicotinamide in Huntington&#x2019;s Disease Models. Mol. Neurobiol. 2017;54:5385&#x2013;5399. doi: 10.1007/s12035-016-0048-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-016-0048-3</ArticleId><ArticleId IdType="pubmed">27590140</ArticleId></ArticleIdList></Reference><Reference><Citation>Caldwell C.C., Petzinger G.M., Jakowec M.W., Cadenas E. Treadmill exercise rescues mitochondrial function and motor behavior in the CAG140 knock-in mouse model of Huntington&#x2019;s disease. Chem. Biol. Interact. 2020;315:108907. doi: 10.1016/j.cbi.2019.108907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cbi.2019.108907</ArticleId><ArticleId IdType="pubmed">31778667</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y., Li C., Tao X., Brazill J.M., Park J., Diaz-Perez Z., Zhai R.G. Nmnat restores neuronal integrity by neutralizing mutant Huntingtin aggregate-induced progressive toxicity. Proc. Natl. Acad. Sci. USA. 2019;116:19165&#x2013;19175. doi: 10.1073/pnas.1904563116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1904563116</ArticleId><ArticleId IdType="pmc">PMC6754563</ArticleId><ArticleId IdType="pubmed">31484760</ArticleId></ArticleIdList></Reference><Reference><Citation>Lloret A., Beal M.F. PGC-1&#x3b1;, Sirtuins and PARPs in Huntington&#x2019;s Disease and Other Neurodegenerative Conditions: NAD+ to Rule Them All. Neurochem. Res. 2019;44:2423&#x2013;2434. doi: 10.1007/s11064-019-02809-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-019-02809-1</ArticleId><ArticleId IdType="pubmed">31065944</ArticleId></ArticleIdList></Reference><Reference><Citation>Chopra V., Quinti L., Kim J., Vollor L., Narayanan K.L., Edgerly C., Cipicchio P.M., Lauver M.A., Choi S.H., Silverman R.B., et al. The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington&#x2019;s disease mouse models. Cell Rep. 2012;2:1492&#x2013;1497. doi: 10.1016/j.celrep.2012.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2012.11.001</ArticleId><ArticleId IdType="pmc">PMC3534897</ArticleId><ArticleId IdType="pubmed">23200855</ArticleId></ArticleIdList></Reference><Reference><Citation>Bobrowska A., Donmez G., Weiss A., Guarente L., Bates G. SIRT2 ablation has no effect on tubulin acetylation in brain, cholesterol biosynthesis or the progression of Huntington&#x2019;s disease phenotypes in vivo. PLoS ONE. 2012;7:e34805. doi: 10.1371/journal.pone.0034805.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0034805</ArticleId><ArticleId IdType="pmc">PMC3325254</ArticleId><ArticleId IdType="pubmed">22511966</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho D.J., Calingasan N.Y., Wille E., Dumont M., Beal M.F. Resveratrol protects against peripheral deficits in a mouse model of Huntington&#x2019;s disease. Exp. Neurol. 2010;225:74&#x2013;84. doi: 10.1016/j.expneurol.2010.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2010.05.006</ArticleId><ArticleId IdType="pubmed">20561979</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong H., Cohen D.E., Cui L., Supinski A., Savas J.N., Mazzulli J.R., Yates J.R., 3rd, Bordone L., Guarente L., Krainc D. Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nat. Med. 2011;18:159&#x2013;165. doi: 10.1038/nm.2559.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2559</ArticleId><ArticleId IdType="pmc">PMC3509213</ArticleId><ArticleId IdType="pubmed">22179316</ArticleId></ArticleIdList></Reference><Reference><Citation>Tulino R., Benjamin A.C., Jolinon N., Smith D.L., Chini E.N., Carnemolla A., Bates G.P. SIRT1 Activity Is Linked to Its Brain Region-Specific Phosphorylation and Is Impaired in Huntington&#x2019;s Disease Mice. PLoS ONE. 2016;11:e0145425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4731418</ArticleId><ArticleId IdType="pubmed">26815359</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu J., Jin J., Cichewicz R.H., Hageman S.A., Ellis T.K., Xiang L., Peng Q., Jiang M., Arbez N., Hotaling K., et al. Trans-(-)-epsilon-Viniferin increases mitochondrial sirtuin 3 (SIRT3), activates AMP-activated protein kinase (AMPK), and protects cells in models of Huntington Disease. J. Biol. Chem. 2012;287:24460&#x2013;24472. doi: 10.1074/jbc.M112.382226.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.382226</ArticleId><ArticleId IdType="pmc">PMC3397871</ArticleId><ArticleId IdType="pubmed">22648412</ArticleId></ArticleIdList></Reference><Reference><Citation>Vis J.C., Schipper E., de Boer-van Huizen R.T., Verbeek M.M., de Waal R.M., Wesseling P., ten Donkelaar H.J., Kremer B. Expression pattern of apoptosis-related markers in Huntington&#x2019;s disease. Acta Neuropathol. 2005;109:321&#x2013;328. doi: 10.1007/s00401-004-0957-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-004-0957-5</ArticleId><ArticleId IdType="pubmed">15668790</ArticleId></ArticleIdList></Reference><Reference><Citation>Paldino E., Cardinale A., D&#x2019;Angelo V., Sauve I., Giampa C., Fusco F.R. Selective Sparing of Striatal Interneurons after Poly (ADP-Ribose) Polymerase 1 Inhibition in the R6/2 Mouse Model of Huntington&#x2019;s Disease. Front. Neuroanat. 2017;11:61. doi: 10.3389/fnana.2017.00061.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnana.2017.00061</ArticleId><ArticleId IdType="pmc">PMC5539174</ArticleId><ArticleId IdType="pubmed">28824383</ArticleId></ArticleIdList></Reference><Reference><Citation>Chidambaram S.B., Vijayan R., Sekar S., Mani S., Rajamani B., Ganapathy R. Simultaneous blockade of NMDA receptors and PARP-1 activity synergistically alleviate immunoexcitotoxicity and bioenergetics in 3-nitropropionic acid intoxicated mice: Evidences from memantine and 3-aminobenzamide interventions. Eur. J. Pharmacol. 2017;803:148&#x2013;158. doi: 10.1016/j.ejphar.2017.03.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2017.03.023</ArticleId><ArticleId IdType="pubmed">28322842</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozdinler P.H., Gautam M., Gozutok O., Konrad C., Manfredi G., Area Gomez E., Mitsumoto H., Erb M.L., Tian Z., Haase G. Better understanding the neurobiology of primary lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21:35&#x2013;46. doi: 10.1080/21678421.2020.1837175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1837175</ArticleId><ArticleId IdType="pmc">PMC8016556</ArticleId><ArticleId IdType="pubmed">33602014</ArticleId></ArticleIdList></Reference><Reference><Citation>Geser F., Stein B., Partain M., Elman L.B., McCluskey L.F., Xie S.X., Van Deerlin V.M., Kwong L.K., Lee V.M., Trojanowski J.Q. Motor neuron disease clinically limited to the lower motor neuron is a diffuse TDP-43 proteinopathy. Acta Neuropathol. 2011;121:509&#x2013;517. doi: 10.1007/s00401-011-0797-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0797-z</ArticleId><ArticleId IdType="pmc">PMC3125638</ArticleId><ArticleId IdType="pubmed">21225272</ArticleId></ArticleIdList></Reference><Reference><Citation>Pourshafie N., Masati E., Bunker E., Nickolls A.R., Thepmankorn P., Johnson K., Feng X., Ekins T., Grunseich C., Fischbeck K.H. Linking epigenetic dysregulation, mitochondrial impairment, and metabolic dysfunction in SBMA motor neurons. JCI Insight. 2020;5:e136539. doi: 10.1172/jci.insight.136539.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.136539</ArticleId><ArticleId IdType="pmc">PMC7406250</ArticleId><ArticleId IdType="pubmed">32641584</ArticleId></ArticleIdList></Reference><Reference><Citation>Scatozza F., Moschella F., D&#x2019;Arcangelo D., Rossi S., Tabolacci C., Giampietri C., Proietti E., Facchiano F., Facchiano A. Nicotinamide inhibits melanoma in vitro and in vivo. J. Exp. Clin. Cancer Res. 2020;39:211. doi: 10.1186/s13046-020-01719-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13046-020-01719-3</ArticleId><ArticleId IdType="pmc">PMC7542872</ArticleId><ArticleId IdType="pubmed">33028392</ArticleId></ArticleIdList></Reference><Reference><Citation>Deguise M.O., Chehade L., Kothary R. Metabolic Dysfunction in Spinal Muscular Atrophy. Int. J. Mol. Sci. 2021;22:5913. doi: 10.3390/ijms22115913.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22115913</ArticleId><ArticleId IdType="pmc">PMC8198411</ArticleId><ArticleId IdType="pubmed">34072857</ArticleId></ArticleIdList></Reference><Reference><Citation>Narver H.L., Kong L., Burnett B.G., Choe D.W., Bosch-Marce M., Taye A.A., Eckhaus M.A., Sumner C.J. Sustained improvement of spinal muscular atrophy mice treated with trichostatin A plus nutrition. Ann. Neurol. 2008;64:465&#x2013;470. doi: 10.1002/ana.21449.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21449</ArticleId><ArticleId IdType="pubmed">18661558</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowerman M., Murray L.M., Scamps F., Schneider B.L., Kothary R., Raoul C. Pathogenic commonalities between spinal muscular atrophy and amyotrophic lateral sclerosis: Converging roads to therapeutic development. Eur. J. Med. Genet. 2018;61:685&#x2013;698. doi: 10.1016/j.ejmg.2017.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmg.2017.12.001</ArticleId><ArticleId IdType="pubmed">29313812</ArticleId></ArticleIdList></Reference><Reference><Citation>Braidy N., Poljak A., Grant R., Jayasena T., Mansour H., Chan-Ling T., Guillemin G.J., Smythe G., Sachdev P. Mapping NAD+ metabolism in the brain of ageing Wistar rats: Potential targets for influencing brain senescence. Biogerontology. 2014;15:177&#x2013;198. doi: 10.1007/s10522-013-9489-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10522-013-9489-5</ArticleId><ArticleId IdType="pubmed">24337988</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson S., Wozniak D.F., Imai S. CA1 Nampt knockdown recapitulates hippocampal cognitive phenotypes in old mice which nicotinamide mononucleotide improves. NPJ Aging Mech. Dis. 2018;4:10. doi: 10.1038/s41514-018-0029-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41514-018-0029-z</ArticleId><ArticleId IdType="pmc">PMC6224504</ArticleId><ArticleId IdType="pubmed">30416740</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>